sb 203580 has been researched along with perfosfamide in 1 studies
Studies (sb 203580) | Trials (sb 203580) | Recent Studies (post-2010) (sb 203580) | Studies (perfosfamide) | Trials (perfosfamide) | Recent Studies (post-2010) (perfosfamide) |
---|---|---|---|---|---|
3,489 | 4 | 1,137 | 328 | 18 | 15 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Chen, KL; Li, XF; Luo, J; Niu, HQ; Qin, KL; Zhao, WP; Zhao, XC | 1 |
1 other study(ies) available for sb 203580 and perfosfamide
Article | Year |
---|---|
Combination of 4-hydroperoxy cyclophosphamide and methotrexate inhibits IL-6/sIL-6R-induced RANKL expression in fibroblast-like synoviocytes via suppression of the JAK2/STAT3 and p38MAPK signaling pathway.
Topics: Arthritis, Rheumatoid; Cells, Cultured; Cyclophosphamide; Drug Therapy, Combination; Fibroblasts; Gene Expression Regulation; Humans; Imidazoles; Interleukin-6; Janus Kinase 2; Methotrexate; p38 Mitogen-Activated Protein Kinases; Pyridines; RANK Ligand; Receptors, Interleukin-6; Signal Transduction; STAT3 Transcription Factor; Synoviocytes; Tyrphostins | 2018 |